Richard A Graham

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. ncbi Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects
    Richard A Graham
    Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Br J Clin Pharmacol 74:788-96. 2012
  2. ncbi Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding
    Richard A Graham
    Genentech Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 17:2512-20. 2011
  3. ncbi A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry
    Richard A Graham
    Genentech, Inc, South San Francisco, CA 94080, USA
    Drug Metab Dispos 39:1460-7. 2011
  4. ncbi Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry
    Yuzhong Deng
    Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, CA 94080, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 879:2119-26. 2011
  5. ncbi Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers
    Richard A Graham
    Genentech, Inc, South San Francisco, CA 94080, USA
    J Cardiovasc Pharmacol 61:83-9. 2013
  6. ncbi Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449)
    Anthony M Giannetti
    Genentech Inc, 1 DNA Way, South San Francisco, California 94080, United States
    J Med Chem 54:2592-601. 2011
  7. ncbi Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer
    Jagath R Junutula
    Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 16:4769-78. 2010

Collaborators

Detail Information

Publications7

  1. ncbi Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects
    Richard A Graham
    Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Br J Clin Pharmacol 74:788-96. 2012
    ..While recent publications have suggested the pharmacokinetics (PK) of vismodegib appear to be non-linear, there has not been a report describing the mechanisms of non-linearity...
  2. ncbi Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding
    Richard A Graham
    Genentech Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 17:2512-20. 2011
    ..We studied the role of GDC-0449 binding to plasma protein alpha-1-acid glycoprotein (AAG) to better understand these unusual pharmacokinetics...
  3. ncbi A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry
    Richard A Graham
    Genentech, Inc, South San Francisco, CA 94080, USA
    Drug Metab Dispos 39:1460-7. 2011
    ..We conclude that vismodegib and any associated metabolic products are mainly eliminated through feces after oral administration in healthy volunteers...
  4. ncbi Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry
    Yuzhong Deng
    Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, CA 94080, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 879:2119-26. 2011
    ..0% of the nominal concentration values. Extraction recovery of vismodegib was between 77.9 and 84.0%. The assay provides a means for accurate assessment of unbound vismodegib plasma concentrations in clinical studies...
  5. ncbi Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers
    Richard A Graham
    Genentech, Inc, South San Francisco, CA 94080, USA
    J Cardiovasc Pharmacol 61:83-9. 2013
    ..Vismodegib was assessed as being of low risk for QT interval prolongation based on prior nonclinical and clinical experience. A dedicated study was conducted to further assess the potential for vismodegib to prolong the QTc interval...
  6. ncbi Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449)
    Anthony M Giannetti
    Genentech Inc, 1 DNA Way, South San Francisco, California 94080, United States
    J Med Chem 54:2592-601. 2011
    ..Molecular docking studies reveal the reason for the signficiant species dependence on binding. These data highlight the utility of biophysical techniques in creating a comprehensive picture of protein binding across species...
  7. ncbi Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer
    Jagath R Junutula
    Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 16:4769-78. 2010
    ..Experimental Design and..